anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods for building muscle tissue in a subject are described, which comprise administering an ellagitannin compound represented by the following formula (I) to a subject in need thereof:The ellagitannin compound represented by the formula (I) may be casuarinin or stachyurin, and is administered in a therapeutically effective amount. For instance, the ellagitannin compound may be administered in an amount effective for activating muscle satellite cells. These methods increase and/or maintain muscle mass, as well as prevent and/or suppress a decrease of muscle mass and/or a decrease of muscle force. In certain embodiments, the subject is a human, such as an elderly person. In particular these methods are useful for subjects having or at risk of diseases such as sarcopenia, locomotive syndrome and/or frailty. The ellagitannin compound represented by the formula (I) may be administered as a component of a food or drink composition.
Myopia onset earlier in children who would suffer a high degree of myopia in the future adulthood.and higher risk for retinal detachment, macular degeneration, and even blindness. In Taiwan, myopia macular degeneration is the first place of irreversible blind cause in the elderly. The evidence based medicine shows atropine is the most effective treatment for the progression of myopia so far, but the side effects including photophobia and near blurred vision often disturbing patients and resulting poor compliance and high drop-out rate.

Recently, the studies from Taiwan and Singapore showed that low concentrations of atropine (0.05% or 0.01%) can effectively inhibit the myopia progression, reduce the symptoms of photophobia, and to achieve favorable myopia control. Previous study found that myopia and allergic conjunctivitis and inflammation were related. The investigators designed a prospective and randomized study to investigate the effect of myopia control in myopic children with ultra low concentrations of atropine eye drops and/or low concentrations of anti-allergic and inflammatory eye drops. Due to environmental factors such as near work, after school class and outdoor activity are also great associated with myopia, the questionnaires also are collected in this study.
PURPOSE:To obtain a skin cleaning and wiping agent, capable of applying a sufficient amount of a solution onto the skin without fouling underwear and having high wiping and protective effects by filling an oil and a propellant under a specific vapor pressure in an aerosol container equipped with a specified jetter. CONSTITUTION:An anhydrous foam cleaning and wiping agent is obtained by filling a stock solution composed of one or two or more oil selected from vegetable oils, animal oils and synthetic oils and a propellant (e.g. liquefied petroleum gas or Freon<gamma>) having 1.0-7.0kg/cm<2> (25 deg.C) vapor pressure in an aerosol container equipped with a valve having 0.20-0.32mm, especially 0.25-0.32mm stem caliber, 0.20-0.32mm, especially 0.25-0.32mm housing caliber and a spout having 2.5-30mm<2>, especially 7-15mm<2> jetting port area or further preferably an aerol container having a button jetting port with 2.0-10mm, especially 4.0-8.0mm caliber. Since the resultant medicine is a foam, the permeation rate to toilet paper is low and its large amount can be applied to the skin in wiping. After the wiping, is not fouled due to disappearance of the foam. Since the medicine is a one-phase system without containing water, is not required and excellent jetting properties are exhibited even at low temperatures.
Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
Compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging) are described.  Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation end products of target proteins, and which additionally reverse pre-formed cross links in the advanced glycosylation end products by cleaving alpha-dicarbonyl-based protein cross links present in the advanced glycosylation end products. Certain agents useful are thiazolium salts. The method employs contacting the target protein with the composition. Both industrial and therapeutic applications for the composition are envisioned, for example food spoilage, animal protein aging and wrinkle reduction. An immunoassay for detection of the reversal of the nonenzymatic cross-linking is also disclosed. Useful agents include thiazolium compounds that have the structural formula (I) wherein RI and R2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl. acetoxy(lower)alkyl, lower alkyl, lower alkenyl, or Rl and R2 together with their ring carbons may be an aromatic fused ring, optionally substituted by one or more amino, halo or alkylenedioxy groups; Z is hydrogen or an amino group; Y is amino, a group of the formula -CH2C=OR wherein R is a lower alkyl, alkoxy, hydroxy, amino or an aryl group, said aryl group optionally substituted by one or more lower alkyl, lower alkoxy, halo, dialkylamino, hydroxy, nitro or alkylenedioxy groups; a group of the formula -CH2R' wherein R' is hydrogen, or a lower alkyl, lower alkynyl, or aryl group or a group of the formula CH2C=OR'NR''' wherein R" is hydrogen and R"' is a lower alkyl group, optionally substituted by an aryl group or an aryl group, said aryl group optionally substituted by one or more lower alkyl, halo, or alkoxylcarbonyl groups; or R" and R"' are both loweralkyl groups; X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion and mixtures thereof, and a carrier therefor. In this case the compounds of formula (I) are formed as biologically and pharmaceutically acceptable salts.  Useful salt forms are the halides, particularly the bromide and chloride, tosylate, methanesulfonate, and mesitylenesulfonate salts.  Other related salts can be formed using similarly non-toxic, and biologically and pharmaceutically acceptable anions. Of the compounds encompassed by formula (I), certain substituents are preferred. For instance, the compounds wherein Rl or R2 are lower alkyl groups are preferred.  Also highly preferred are the compounds wherein Y is an amino group, a 2-amino-2oxoethyl group, a 2-phenyl-2-oxoethyl or a 2-[substituted phenyl]-2-oxoethyl group. Representative compounds include: 3-aminothiazolium mesitylenesulfonate 3-(2-methoxy-2-oxoethyl)-thiazolium bromide 3-(2-methyl-2-oxoethyl)thiazolium chloride
Subjects will be administered with Lemborexant(LEM). The dosage of LEM is 5 mg or 10mg taken no more than once per night during the study.
Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. The formulation may be dispersed in a suture or adhesive for administration at the time of or as released following suturing or gluing of a wound, thereby limiting bleeding, loss of tissue fluids, or other fluids such as those produced by parenchymal tissues such as the liver, pancreas, and gastrointestinal tract. The formulation may be applied to any site of bleeding, in a bandage, gauze, sponge, or other material, for immediate control of bleeding, or released later to control bleeding if the initial treatment such as suturing or pressure is insufficient. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate. In another embodiment, the formulation is provided as a coating on a device, for example a stent or a catheter. The material is also useful to isolate tissue, for preservation of tissue for subsequent transplantation or reattachment, and as a bulking, stabilizing or hydrating agent.
The Cal-PAT study is a multi-centered, prospective, observational cohort study. From March 2015 to July 2017, patients ≥ 18-years-old who sustained blunt or penetrating trauma with signs of hemorrhagic shock identified were considered for TXA treatment by first responders in the prehospital setting and physicians in hospital. A control group was formed of patients seen in the five years prior to data collection cessation (June 2012 to July 2017) at each receiving center who were not administered TXA. Control group patients were selected through propensity score matching based on gender, age, injury severity scores, and mechanism of injury. The primary outcome measured was mortality. Secondary outcomes measured included the total blood products transfused, the hospital and intensive care unit length of stay, and the incidence of known adverse events associated with TXA.
The investigators will perform an open-label case series to evaluate the feasibility of performing a trial of a novel intervention to reduce postpartum depression symptoms after cesarean delivery. The intervention, Perinatal SMILES (Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms), combines interpersonal therapy with subcutaneous ketamine therapy. The interpersonal therapy consists of five sessions that will be administered during the antepartum and/or postpartum. The ketamine therapy will be administered as two injections, approximately 24 hours apart, in the first four postpartum days and will be preceded and followed by additional therapy sessions. The investigators will assess brain electronic activity before and after the ketamine injections and mood in the first 12 postpartum weeks. The objective is to determine the feasibility of recruiting participant, administering the intervention and collect the outcome data.
Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease characterized by parkinsonism, cerebellar syndrome, and autonomic failure. Dysphagia is a clinically significant symptom leading to pneumonia that causes death in patients with MSA. Although the symptoms of dysphagia in the two subtypes of MSA-the parkinsonian variant and the cerebellar variant- are different, there is no significant difference in the latency to onset of tube feeding. Therefore, effective intervention is needed to improve the safety and efficiency of swallowing regardless of the subtypes of MSA.

Although swallowing rehabilitation has been widely applied for swallowing disorders in patients with MSA, few studies have reported the clinical effect of applying swallowing therapy. Comprehensive swallowing rehabilitation has focused on functional muscle training, compensatory swallowing maneuvers, and thermal-tactile stimulation, which is used to treat dysphagia from stroke, Parkinson's disease, and head and neck cancer. Therefore, this study aims to investigate the effect of comprehensive swallowing rehabilitation in patients with MSA.
The present disclosure generally relates to evaluating medical images. Some embodiments access stored medical images, provide a form template construction application to a coordinating user, and provide review applications to reviewing users. The form template construction application provides a tool for creating on a form template at least one user control for designating a region on a medical image and a tool for creating on a form template at least one user input for receiving diagnosis data about a medical image. The form template construction application distributes review forms based on the form template to the reviewing users. The reviewing users provide review data for each image, such an identification of a region and a corresponding diagnosis. A central server collects the review data from the reviewing users and stores it for use by the coordinating user.
Teeth are the hardest and most chemically stable tissues in the body, are well-preserved in archaeological remains and, being resistant to decomposition in the soil, survive long after their supporting structures have deteriorated. It has long been recognised that visual and radiographic examination of teeth can provide considerable information relating to the lifestyle of an individual. This paper examines the latest scientific approaches that have become available to investigate recent and ancient teeth. These techniques include DNA analysis, which can be used to determine the sex of an individual, indicate familial relationships, study population movements, provide phylogenetic information and identify the presence of disease pathogens. A stable isotopic approach can shed light on aspects of diet and mobility and even research climate change. Proteomic analysis of ancient dental calculus can reveal specific information about individual diets. Synchrotron microcomputed tomography is a non-invasive technique which can be used to visualise physiological impactful events, such as parturition, menopause and diseases in cementum microstructure - these being displayed as aberrant growth lines.
PURPOSE:To obtain a pretreating agent capable of improving force of bonding to a curable resin composition by application to the surface of dentin. CONSTITUTION:A pretreating agent for dentin comprises 100 pts.wt. total amounts of (A) 0.001-95 pts.wt., preferably 0.05-50 pts.wt. sulfur-containing reducing inorganic compound, preferably a reducing inorganic compound containing a sulfur among redox polymerization initiators useful in polymerization of a radically polymerizable monomer in a medium such as water, especially sodium (hydrogen)sulfite or potassium (hydrogen)sulfite and (B) 5-99.999 pts.wt., preferably 50-99.95 pts.wt. aqueous solvent, preferably mixed solution of water and ethanol or water and acetone. Both the components are premixed and applied to dentin or blended on dentin and applied. The pretreating agent can be directly applied to dentin but preferably the surface of dentin is pretreated with an etching agent and the pretreating agent is applied to dentin.
A tactile display device including a nodule having variable stiffness under a surface to provide a near-real feeling of palpation for a physician. The device utilizes granular jamming technology using pneumatic actuation to control a nodule that maintains its shape while allowing the modulation in stiffness. The nodule includes two hemispheres, a contact portion and an actuation portion, forming a sphere. The contact portion and the actuation portion include different thicknesses and/or materials, while the dimensions of the dimensions of the nodule are maintained. As such, a physician can utilize the device to identify the difference between a normal lump and an affected lump even if the shape of each lump appears to be the same. With the tactile display device, due to the different levels of stiffness, a physician can detect the severity of the lump.
Respiratory allergy often begins in childhood and most commonly manifests as allergic rhinitis (upper airways) and/or asthma (lower airways). Children with upper respiratory allergy often suffer from coexisting asthma, and other comorbidities ranging from gastrointestinal disorders to emotional/mental health disorders. Consequently, the disease burden is considerable and profoundly impacts a child's daily life. Early identification and appropriate management are important to reduce disease burden, lower the risk of disease progression and additional comorbidities, and protect the child's future well-being. A window of opportunity for halting disease progression may open in the early stages of allergic disease and underlines the importance of early diagnosis and treatment of children at risk. This review offers advice on identifying children with a high disease burden who would benefit from early intervention. Allergen immunotherapy (AIT) modifies the cause of respiratory allergy and prevents disease progression. In clinical practice, AIT could be considered as an early treatment for eligible children, to achieve long-term symptom control and disease modification.
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
The aim of each extension cohort is to provide preliminary evidence of anti-tumor activity while refining toxicity data, and to gain insight progressive disease activity and exploratory biological analyses. A maximum of 14 patients patients will be enrolled in this cohort " Soft-tissue sarcomas with MDM2 amplification ". Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Adeno-associated virus (AAV) is a defective single-stranded DNA virus that is prevalent in the human population (35-80%). Recurrent clonal AAV2 insertion was associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) occurring in the normal liver. The inventors' objective was to characterize the natural history of AAV infection in the liver. Thus, viral DNA was quantified in tumor and non-tumor liver tissue of 1461 patients. The presence of episomal forms and viral mRNA expression were analyzed using DNAse/TaqMan based assays and quantitative RT-PCR. Computer analysis using virus capture data identified viral variants and new clonal insertions. AAV DNA was detected in 21% of patients, evenly distributed among two major viral subtypes: one is similar to AAV2, and the other is a hybrid between AAV2 and AAV13 sequences. Thus, the inventors provide a comprehensive analysis of wild-type AAV infection in the liver by identifying viral genotype, molecular form, helper virus relationship, and viral integration. These findings are important for understanding wild-type AAV biology, particularly in relation to the large number of uses of AAV vectors in liver-targeted gene therapy. Accordingly, the present invention relates to novel adeno-associated virus (AAV) variants and their use for gene therapy.
PCT No. PCT/GB84/00239 Sec. 371 Date Mar. 18, 1985 Sec. 102(e) Date Mar. 18, 1985 PCT Filed Jul. 4, 1984 PCT Pub. No. WO85/00521 PCT Pub. Date Feb. 14, 1985.Known disadvantages of protein Ca are overcome or reduced by acylating the protein to form a derivative which will gradually hydrolyse in vivo to regenerate the active enzyme. The enzyme derivative comprises protein Ca in which the active site essential for anti-coagulant activity is blocked by an acyl group removable in vivo by enzymatic hydrolysis to provide a sustained and controlled release of protein Ca, preferred acyl groups being optionally substituted benzoyl or acryloyl groups.
PURPOSE: A Met inhibitor used for treating cancer is provided to strengthen radiation efficacy. CONSTITUTION: A Met inhibitor used for treating cancer contains: an anti-Met monoclonal antibody; a genetically manipulated antibody containing complementarity determining regions(CDRs) of the anti-Met monoclonal antibody; and a fragment containing the CDRs or combination thereof. A nucleotide sequence encoding the Met inhibitor is administered by a vector of a particular form. The fragment is a Fab fragment containing a stabilization molecule. The stabilization molecule is polyethylene glycol, albumin binding domain, or albumin. [Reference numerals] (AA) Living cells%; (BB) Vehicle
Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
A computer-implemented method for generating a tumor fraction estimate from a DNA sample of a subject is disclosed. The method may include receiving a dataset of methylation sequence reads from the sample of the subject. The method may also include dividing the dataset into a plurality of variants. The method may further include determining methylation states of the plurality of variants. The method may further include filtering the plurality of variants based on a bank of reference sequence reads to generate a filtered subset of variants. The bank may include reads generated from non-cancer samples and biopsy samples of a plurality of tissues of reference individuals. The counts of the methylation states of variants in the filtered subset are determined and input to a model that is trained based on recurrence rates of the variants in the reference sequence reads. The tumor fraction estimate may be generated by the model.
The process comprises reaction of 2,3-epoxy-(6-methoxy -2-naphthyl)-alkyl butyrate, of formula (I) in which R is C1-4 alkyl, with an alkaline alcoholate, at ambient temp. To increase efficiency, the reaction is followed by disproportionation of the product through heating at 140 deg.C, in a conc. soln. of NaOH. After extn. of the alcohol with xylene, the alkaline salt of the acid is acidified with inorganic acid.
The term "toe walking" describes walking on the toes with a lack of heel strike upon initiation of the stance phase of gait. In individuals with autism spectrum disorder (ASD), this phenomenon, or "tip-toe behavior" (TTB), can be present in a substantial proportion of subjects even during standing. In this study, we investigated TTB in 50 persons with ASD (age range 4-26 years). We evaluated TTB through an observational/report-based assessment protocol. Subsequently, we employed a new structured video-based coding protocol based on standardized video recordings, focusing on static and dynamic conditions. Finally, the findings of the two protocols were compared. Twenty-four subjects with TTB were identified and classified according to three functional groups: TTB1, present only during running (6 subjects); TTB2, present during walking and running (11 subjects); and TTB3, present during standing, walking, and running (7 subjects). Moreover, we found that TTB3 subjects exhibited a significantly higher quantity of TTB compared with subjects in the TTB1 and TTB2 groups during both standing and walking tests. Additionally, a high quantity of TTB in the static test was found to be related to a high quantity of TTB in the dynamic test. Variables such as age, autism severity, intellectual disability, and gender were not significantly associated with the mean percent of TTB both in static and dynamic tests in multivariate analysis. This structured video-based coding approach appears feasible and useful for assessing TTB in individuals with ASD and it has the potential to provide insights into TTB trajectories and aid in designing possible interventions.